Anti-Hu p53 (pS392) Purified

Anti-Hu p53 (pS392) Purified
Regulatory status
RUO
Antigen
p53 (pS392)
Clone
FP3.2 [FPS392]
Format
Purified
Reactivity
Human
Application
WB, IHC(P)
Variant
0.1 mg
11-467-C100
In stock

0.025 mg
11-467-C025
In stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
Images
References
Isotype
Mouse IgG1
Specificity
The antibody FP3.2 [FPS392] reacts with human p53 tumour suppressor protein phosphorylated at CKII site (Ser 392).
Application
WB, IHC(P)
Reactivity
Human
Immunogen
KLH-conjugated phosphopeptide RHKKLMFKTEGPDS[P]D, corresponding to amino acids 378-393 of human p53.
Other names
BCC7, TRP53, TP53, LFS1
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.
11-467 IHC
Immunohistochemistry staining of Wild-type p53 expressed in human trophoblast (paraffin-embedded sections). A – anti-p53 (total) B – anti-p53 (phospho Ser392) Note that some of total p53 positive nuclei are also FP3.2 (phospho p53) positive.

General references:

Tanigawa S, Fujii M, Hou DX: Stabilization of p53 is involved in quercetin-induced cell cycle arrest and apoptosis in HepG2 cells. Biosci Biotechnol Biochem. 2008 Mar;72(3):797-804.
PubMed
Taylor WR, Agarwal ML, Agarwal A, Stacey DW, Stark GR: p53 inhibits entry into mitosis when DNA synthesis is blocked. Oncogene. 1999 Jan 14;18(2):283-95.
PubMed
Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schönthal AH, Katula KS, Stark GR: Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell. 1999 Nov;10(11):3607-22.
PubMed
Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y, Stark GR: A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14775-80.
PubMed
Agarwal ML, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8493-7.
PubMed

Product specific references:

Blaydes JP, Craig AL, Wallace M, Ball HM, Traynor NJ, Gibbs NK, Hupp TR: Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene. 2000 Aug 10;19(34):3829-39.
PubMed
Sikorski K, Mehta A, Inngjerdingen M, Thakor F, Kling S, Kalina T, Nyman TA, Stensland ME, Zhou W, de Souza GA, Holden L, Stuchly J, Templin M, Lund-Johansen F: A high-throughput pipeline for validation of antibodies. Nat Methods. 2018 Nov;15(11):909-912.
PubMed
Variant
0.1 mg
11-467-C100
In stock

0.025 mg
11-467-C025
In stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock